Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-101 in Healthy Subjects and Patients With Chronic Hepatitis B
NCT06746311Phase 1Completed
- Sponsor
- Hepatera
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HT-101 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Hepatera. Primary endpoints: Incidence of adverse events and serious adverse events at 24 weeks and Clinically significant abnormalities at 24 weeks. Started Nov 2022; status: completed.
02
Drugs
HT-101
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06746311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746311.